Oncologists Likely to Get Small Medicare Increases

Publication
Article
OncologyONCOLOGY Vol 13 No 9
Volume 13
Issue 9

Anyone who remembers the bruising political battle in 1997-1998over how Medicare would develop “resource-based” practice expenses can breathe a sign of relief over what is likely to be the painless shift to resource-based malpractice

Anyone who remembers the bruising political battle in 1997-1998over how Medicare would develop “resource-based” practice expenses can breathe a sign of relief over what is likely to be the painless shift to resource-based malpractice expenses. Medicare will work them into its payment formula starting January 1, 2000. That formula takes into account three relative value units (RVUs): for work (accounts for 54.5% of the total payment), practice expense (42.3%), and malpractice expense (3.2%). These three RVUs are added together and then multiplied by a conversion factor of $34.73. The fact that malpractice expenses are such a small part of the formula explains why payment for hematology/oncology codes will increase only 0.3 in 2000, which is fairly typical for most specialties. Medicare also wants to refine some of its practice expense RVUs. That would give hematology/oncology a 1% increase in 2002 over what payments would have been otherwise.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The phase 3 NIVOSTOP trial evaluated an anti–PD-1 immunotherapy, nivolumab, in a patient population similar in the KEYNOTE-689 trial.
CAR T-cell therapies appear to be an evolving modality in the treatment of those with intracranial tumors, said Sylvia Kurz, MD, PhD.
Opportunities to further reduce relapses include pembrolizumab-based combination therapy and evaluating the agent’s contribution before and after surgery.
For patients with locally advanced head and neck cancers, the current standard of care for curative therapy has a cure rate of less than 50%.
According to Maurie Markman, MD, patient-reported outcomes pertain to more relevant questions surrounding the impact of therapy for patients.
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Related Content